<DOC>
	<DOCNO>NCT00993044</DOCNO>
	<brief_summary>This phase I study design determine maximum tolerate dose Irinotecan give intravenous 5 day every 3 week combination fix dose Vincristine , Temozolomide Bevacizumab ( VIT-B ) patient refractory solid tumor .</brief_summary>
	<brief_title>A Study Vincristine , Escalating Doses Irinotecan , Temozolomide Bevacizumab ( Vit-b ) Pediatric Adolescent Patients With Recurrent Refractory Solid Tumors Non-hematopoietic Origin</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age : Patients must &gt; 12 month &lt; 21 year age time study entry . Weight : Patient must equal 10 Kilograms . Histological Diagnosis : Patients must histological verification malignancy time prior study entry . All solid tumor eligible exclusion lymphoma . For patient neuroblastoma , diagnosis base elevate catecholamine urine tumor cell bone marrow aspirates/biopsies acceptable . For patient germ cell tumor , diagnosis base elevated tumor marker ( serum alpha fetoprotein and/or serum beta human chorionic gonadotropin ) radiographic evidence disease acceptable . Disease Status : Disease must fail standard therapy ( therapy ) disease standard therapy exists . Patient stable disease therapy eligible . Performance Level : Karnofsky &gt; 50 % patient &gt; 16 year age Lansky &gt; 50 child &lt; 16 year age ( Appendix I ) . Life Expectancy : Must &gt; 8 week . Patients receive bevacizumab and/or Irinotecan previously ineligible . Non brain tumor patient previously receive Temozolomide ineligible . Pregnancy BreastFeeding : Pregnant patient ineligible study due know teratogenic effect cytotoxic agent . Pregnancy test must obtain female childbearing potential prior enrollment . Lactating woman must agree breastfeed . Males female reproductive age may participate unless agree use effective contraceptive method . Patients Who Have Uncontrolled Infection eligible enrollment infection control . Clinically Significant Unrelated Systemic Illness : Patients serious infection significant pulmonary , hepatic , renal , endorgan dysfunction judgment Principal CoInvestigators would compromise patient 's ability tolerate prescribe chemotherapy likely interfere study procedure result eligible .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>